 |
|
|
| |
A Phase 1 Study to Evaluate the Interaction of HCV NS5B Inhibitor MK-3682 With HCV NS3/4A Protease Inhibitor MK-5172 and HCV NS5A Inhibitor MK-8408 in Healthy Subjects
|
| |
| |
Reported by Jules Levin
EASL 2015 Apr 22-26 Vienna, Austria
Xiao-Jian Zhou1; Eric Sicard2; Jie Chen1; Dodie Frank1; Wei Gao3; Matthew L. Rizk3; Elizabeth G. Rhee3; Joan R. Butterton3; John Sullivan-Bolyai1
1Idenix Pharmaceuticals Inc., a wholly owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; 2Algorithme Pharma, Montreal, Quebec, Canada; 3Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
